New News information at Drug Development Technology New and updated information from News listed on www.drugdevelopment-technology.com http://www.drugdevelopment-technology.com/ en-us http://www.drugdevelopment-technology.com/ New News information at Drug Development Technology http://www.drugdevelopment-technology.com/content/images/logo_big.gif Deals this week: Sanofi, Breckenridge Pharmaceuticals, VBI Vaccines http://www.drugdevelopment-technology.com/news/newsdeals-this-week-sanofi-breckenridge-pharmaceuticals-vbi-vaccines-inc-5691221 http://www.drugdevelopment-technology.com/news/newsdeals-this-week-sanofi-breckenridge-pharmaceuticals-vbi-vaccines-inc-5691221 Sanofi and JHL Biotech have entered an agreement to expand their presence and develop modern therapies for patients in China. Fri, 09 Dec 2016 00:00:00 GMT Myeloma XI’s Phase III trial result shows increase in myeloma patient remission http://www.drugdevelopment-technology.com/news/newsmyeloma-xis-phase-iii-trial-result-shows-increase-in-myeloma-patient-remission-5691442 http://www.drugdevelopment-technology.com/news/newsmyeloma-xis-phase-iii-trial-result-shows-increase-in-myeloma-patient-remission-5691442 Myeloma XI has reported that the Phase III trial conducted in myeloma has indicated a 95% increase in progression-free survival (PFS) in myeloma patients receiving lenalidomide maintenance treatment. Thu, 08 Dec 2016 00:00:00 GMT AXIM Biotechnologies secures approval in Netherlands for IBS trial for CBD product http://www.drugdevelopment-technology.com/news/newsaxim-biotechnologies-secures-approval-in-netherlands-for-ibs-trial-for-cbd-product-5691509 http://www.drugdevelopment-technology.com/news/newsaxim-biotechnologies-secures-approval-in-netherlands-for-ibs-trial-for-cbd-product-5691509 AXIM Biotechnologies has secured approval from the Medical Ethical Committee (METC) of Wageningen University in the Netherlands to commence a trial on patients suffering from irritable bowel syndrome (IBS) with its product CanChew Plus CBD-containing… Thu, 08 Dec 2016 00:00:00 GMT Mast Therapeutics begins enrolment for Phase II INABLE-TRAINING study of AIR001 to treat HFpEF http://www.drugdevelopment-technology.com/news/newsmast-therapeutics-starts-enrolling-for-phase-ii-inable-training-study-of-air001-to-treat-hfpef-5691531 http://www.drugdevelopment-technology.com/news/newsmast-therapeutics-starts-enrolling-for-phase-ii-inable-training-study-of-air001-to-treat-hfpef-5691531 US-based biopharmaceutical company Mast Therapeutics has begun enrolment for its Phase II INABLE-TRAINING study of AIR001 to treat heart failure with preserved ejection fraction (HFpEF). Thu, 08 Dec 2016 00:00:00 GMT TherapeuticsMD reports Phase III Replenish Trial positive top-line data of TX-001HR to treat VMS http://www.drugdevelopment-technology.com/news/newstherapeuticsmd-reports-phase-iii-replenish-trial-positive-top-line-data-of-tx-001hr-to-treat-vms-5688245 http://www.drugdevelopment-technology.com/news/newstherapeuticsmd-reports-phase-iii-replenish-trial-positive-top-line-data-of-tx-001hr-to-treat-vms-5688245 US-based healthcare company TherapeuticsMD has reported positive top-line results of its pivotal Phase III Replenish Trial of TX-001HR to treat moderate-to-severe vasomotor symptoms (VMS) due to menopause in post-menopausal women with an intact uteru… Wed, 07 Dec 2016 00:00:00 GMT Noveome begins Phase II trial of ST266 to treat allergic conjunctivitis http://www.drugdevelopment-technology.com/news/newsnoveome-begins-phase-ii-trial-of-st266-to-treat-allergic-conjunctivitis-5687962 http://www.drugdevelopment-technology.com/news/newsnoveome-begins-phase-ii-trial-of-st266-to-treat-allergic-conjunctivitis-5687962 US-based clinical stage biotherapeutics company Noveome has begun its Phase II clinical trial of ST266 to treat allergic conjunctivitis. Wed, 07 Dec 2016 00:00:00 GMT G1 Therapeutics and Genentech to evaluate Phase II lung cancer trial of tecentriq and trilaciclib http://www.drugdevelopment-technology.com/news/newsg1-therapeutics-and-genentech-to-evaluate-phase-ii-lung-cancer-trial-of-tecentriq-and-trilaciclib-5687413 http://www.drugdevelopment-technology.com/news/newsg1-therapeutics-and-genentech-to-evaluate-phase-ii-lung-cancer-trial-of-tecentriq-and-trilaciclib-5687413 US-based clinical-stage oncology company G1 Therapeutics has collaborated with Genentech to conduct a Phase II clinical trial of tecentriq and trilaciclib to treat patients with small-cell lung cancer (SCLC) receiving chemotherapy. Wed, 07 Dec 2016 00:00:00 GMT CSL Behring reports positive Phase III PROLONG-9FP trial data of IDELVION to treat haemophilia B http://www.drugdevelopment-technology.com/news/newscsl-behring-reports-positive-phase-iii-prolong-9fp-trial-data-of-idelvion-to-treat-hemophilia-b-5686968 http://www.drugdevelopment-technology.com/news/newscsl-behring-reports-positive-phase-iii-prolong-9fp-trial-data-of-idelvion-to-treat-hemophilia-b-5686968 Australian CSL's US biotherapeutics subsidiary CSL Behring has reported positive results from its Phase III PROLONG-9FP clinical development programme of IDELVION to treat haemophilia B. Tue, 06 Dec 2016 00:00:00 GMT Novartis reports positive Phase II SUSTAIN study results of SEG101 to treat SCPC http://www.drugdevelopment-technology.com/news/newsnovartis-reports-positive-phase-ii-sustain-study-results-of-seg101-to-treat-scpc-5686967 http://www.drugdevelopment-technology.com/news/newsnovartis-reports-positive-phase-ii-sustain-study-results-of-seg101-to-treat-scpc-5686967 Novartis has reported positive data from its Phase II SUSTAIN study of SEG101 (crizanlizumab) to treat sickle-cell-related pain crises (SCPC). Tue, 06 Dec 2016 00:00:00 GMT Janssen-Cilag reports long-term follow-up data from Phase III RESONATE-2 trial of Ibrutinib to treat CLL http://www.drugdevelopment-technology.com/news/newsjanssen-cilag-reports-long-term-follow-up-data-from-phase-iii-resonate-2-trial-of-ibrutinib-to-treat-cll-5688340 http://www.drugdevelopment-technology.com/news/newsjanssen-cilag-reports-long-term-follow-up-data-from-phase-iii-resonate-2-trial-of-ibrutinib-to-treat-cll-5688340 Janssen-Cilag has reported positive long-term follow-up results from its Phase III RESONATE-2 trial of Ibrutinib to treat chronic lymphocytic leukaemia (CLL). Tue, 06 Dec 2016 00:00:00 GMT Western University to initiate Phase II human trial of HIV vaccine http://www.drugdevelopment-technology.com/news/newswestern-university-to-initiate-phase-ii-human-trial-of-hiv-vaccine-5685622 http://www.drugdevelopment-technology.com/news/newswestern-university-to-initiate-phase-ii-human-trial-of-hiv-vaccine-5685622 The research team at Western University’s Schulich School of Medicine & Dentistry are planning to put their HIV vaccine (SAV001) into Phase II human clinical trials. Mon, 05 Dec 2016 00:00:00 GMT Cytokinetics initiates Phase III trial of omecamtiv mecarbil to treat chronic heart failure http://www.drugdevelopment-technology.com/news/newscytokinetics-initiates-phase-iii-trial-of-omecamtiv-mecarbil-to-treat-chronic-heart-failure-5686041 http://www.drugdevelopment-technology.com/news/newscytokinetics-initiates-phase-iii-trial-of-omecamtiv-mecarbil-to-treat-chronic-heart-failure-5686041 US-based late-stage biopharmaceutical company Cytokinetics has initiated its Phase III GALACTIC-HF clinical trial of omecamtiv mecarbil to treat patients experiencing chronic heart failure. Mon, 05 Dec 2016 00:00:00 GMT Basilea expands ongoing Phase I/IIa clinical trial of BAL101553 to include glioblastoma patients http://www.drugdevelopment-technology.com/news/newsbasilea-expands-ongoing-phase-iiia-clinical-trial-of-bal101553-to-include-glioblastoma-patients-5686601 http://www.drugdevelopment-technology.com/news/newsbasilea-expands-ongoing-phase-iiia-clinical-trial-of-bal101553-to-include-glioblastoma-patients-5686601 Swiss biopharmaceutical company Basilea has expanded its ongoing Phase I/IIa clinical trial of BAL101553 to include adult patients with recurrent or progressive glioblastoma. Mon, 05 Dec 2016 00:00:00 GMT New study reveals hallucinogenic drug psilocybin reduces cancer patients' distress http://www.drugdevelopment-technology.com/news/newsnew-study-reveals-hallucinogenic-drug-psilocybin-reduces-cancer-patients-distress-5685691 http://www.drugdevelopment-technology.com/news/newsnew-study-reveals-hallucinogenic-drug-psilocybin-reduces-cancer-patients-distress-5685691 A new study conducted by NYU Langone Medical Center researchers has revealed that a single dose of hallucinogenic drug psilocybin relieves anxiety and depression in patients with advanced cancer. Fri, 02 Dec 2016 00:00:00 GMT Deals this week: Teva Pharma, Boston Children’s Hospital, MedImmune http://www.drugdevelopment-technology.com/news/newsdeals-this-week-teva-pharma-boston-childrens-hospital-medimmune-5684938 http://www.drugdevelopment-technology.com/news/newsdeals-this-week-teva-pharma-boston-childrens-hospital-medimmune-5684938 Teva Pharma Industries and Syqe Medical have entered an agreement to market medical cannabis inhalers in Israel. Fri, 02 Dec 2016 00:00:00 GMT Novan reports positive top-line data from Phase II clinical trial of SB206 against HPV http://www.drugdevelopment-technology.com/news/newsnovan-reports-positive-top-line-data-from-phase-ii-clinical-trial-of-sb206-against-hpv-5685191 http://www.drugdevelopment-technology.com/news/newsnovan-reports-positive-top-line-data-from-phase-ii-clinical-trial-of-sb206-against-hpv-5685191 US-based pharmaceutical company Novan has reported positive top-line results from its Phase II clinical trial of SB206 to treat genital warts caused by human papillomavirus (HPV). Fri, 02 Dec 2016 00:00:00 GMT M&As this week: Shenzhen Neptunus Bioengineering, Korea Value Asset Management, Catalent http://www.drugdevelopment-technology.com/news/newsmas-this-week-shenzhen-neptunus-bioengineering-korea-value-asset-management-catalent-inc-5684954 http://www.drugdevelopment-technology.com/news/newsmas-this-week-shenzhen-neptunus-bioengineering-korea-value-asset-management-catalent-inc-5684954 Shenzhen Neptunus Bioengineering plans to acquire a 70% stake in a pharmaceutical company based in Hunan, China. Fri, 02 Dec 2016 00:00:00 GMT MicuRx begins Phase I trial of MRX-4 against Gram-positive bacteria http://www.drugdevelopment-technology.com/news/newsmicurx-starts-phase-i-trial-of-mrx-4-against-gram-positive-bacteria-5683157 http://www.drugdevelopment-technology.com/news/newsmicurx-starts-phase-i-trial-of-mrx-4-against-gram-positive-bacteria-5683157 US-based biopharmaceutical company MicuRx has begun its Phase I clinical trial of MRX-4, for the treatment of infections caused by Gram-positive bacteria, including methicillin-resistant S. aureus (MRSA) and vancomycin-resistant Enterococci (VRE). Thu, 01 Dec 2016 00:00:00 GMT Cerecor’s Phase II clinical trial of CERC-301 to treat MDD fails to meet primary endpoint http://www.drugdevelopment-technology.com/news/newscerecors-phase-ii-clinical-trial-of-cerc-301-to-treat-mdd-fails-to-meet-primary-endpoint-5683370 http://www.drugdevelopment-technology.com/news/newscerecors-phase-ii-clinical-trial-of-cerc-301-to-treat-mdd-fails-to-meet-primary-endpoint-5683370 US-based clinical-stage biopharmaceutical company Cerecor has reported that its Phase II clinical trial of CERC-301 to treat major depressive disorder (MDD) has failed to meet its primary endpoint. Thu, 01 Dec 2016 00:00:00 GMT Innate Pharma reports positive Phase I/II trial data of monalizumab for advanced gynecologic malignancies http://www.drugdevelopment-technology.com/news/newsinnate-pharma-reports-positive-phase-iii-trial-data-of-monalizumab-for-advanced-gynecologic-malignancies-5683744 http://www.drugdevelopment-technology.com/news/newsinnate-pharma-reports-positive-phase-iii-trial-data-of-monalizumab-for-advanced-gynecologic-malignancies-5683744 French clinical-stage biotechnology company Innate Pharma has reported positive data from its dose-ranging part of a Phase I/II trial of monalizumab to treat advanced gynecologic malignancies. Thu, 01 Dec 2016 00:00:00 GMT